SCHEMBL24547734

SCHEMBL24547734

Nc1nc2cnc(C(=O)N3CCOCC3)cc2c2c1COC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.45
HPGD P15428 3/20 0.40
ALDH1A1 P00352 3/20 0.40
TP53 P04637 3/20 0.40
KDM4E B2RXH2 2/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
TSHR P16473 2/20 0.39
ESR2 Q92731 1/20 0.39
GRM5 P41594 1/20 0.38
LMNA P02545 2/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
JAK2 O60674 1/20 0.37
PDE4B Q07343 1/20 0.37
HTR2C P28335 1/20 0.36
CCNE1 P24864 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27267989 0.91 CNR1 (0.42) HPGDALDH1A1CCNCCDK8NPC1
SCHEMBL24547740 0.89 RAB9A (0.36) SMN1; SMN2HPGDALDH1A1TP53KDM4E
SCHEMBL24547768 0.89 NCF1 (0.36) SMN1; SMN2NPC1RAB9ACCNE1CDK2
SCHEMBL29650940 0.81 KDM4E (0.35) SMN1; SMN2HPGDALDH1A1KDM4EALOX15
SCHEMBL24468603 0.81 KDM4E (0.35) SMN1; SMN2HPGDALDH1A1KDM4EALOX15
SCHEMBL29686097 0.80 KDM4E (0.32) KDM4E
SCHEMBL24468209 0.80 KDM4E (0.32) KDM4E
Hydrochloric Acid SCHEMBL29686221 0.79 KDM4E (0.31) KDM4E
Hydrochloric Acid SCHEMBL29106338 0.79 KDM4E (0.31) KDM4E
SCHEMBL24540849 0.79 CCNE1 (0.37) CCNCCDK8CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024118897-A1 CANCER TREATMENTS USING A PRMT5 INHIBITOR AND A MAT2A INHIBITOR AMGEN INC. (US) 2024-06-06 WO disclosed
WO-2022132914-A1 PRMTS INHIBITORS AMGEN INC. (US) 2022-06-23 WO disclosed